12 results about "Mydriasis" patented technology

The invention discloses a deuterated compound of benzodiazepine and application thereof, the deuterated compound of benzodiazepine has the following general formula: in the formula, R1 and R2 are independently selected from ethyl or deuterated ethyl, R3 to R18 are independently selected from H group or deuterated group, and R1 to R18 at least contain one deuterated group. The deuterated compound of benzodiazepine or the pharmaceutically acceptable salt, hydrate or solvent compound thereof provided by the invention has a muscarinic M2 receptor antagonism effect, and compared with a known selective M2 receptor inhibitor, the compound provided by the invention has better inhibitory activity and pharmacodynamic performance, has little influence on the activity of an M3 receptor, and can be used for preparing a novel compound of benzodiazepine or a pharmaceutically acceptable salt, hydrate or solvent compound of benzodiazepine. The side effect of pupil dilation (mydriasis) is avoided, and the composition has a good development prospect in clinical application of treating myopia, preventing myopia and / or inhibiting myopia development.

Disclosed are a deuterated compound of benzodiazepine, and a use thereof. The deuterated compound of benzodiazepine has the following general formula (I), R1 and R2 being independently selected from ethyl or deuterated ethyl, R3-R18 being independently selected from hydrogen or deuterium, and R1-R18 containing at least one deuterium. The deuterated compound of benzodiazepine provided by the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, has antagonistic activity against muscarinic M2 receptors. Compared with known selective M2 receptor inhibitors, the compound of the present invention has better inhibitory activity and pharmacodynamic properties, and has minimal activity on M3 receptors, thereby avoiding the side effect of pupil dilation (mydriasis). It has promising prospects for clinical applications in treating myopia, preventing myopia, and / or inhibiting the progression of myopia.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The application discloses a method for establishing an angle-closure glaucoma animal model. The method comprises the following steps: performing mydriasis on an eye of an animal model after general anesthesia, performing local anesthesia on an eye surface of the model eye after 10 minutes; after the pupil of the model eye is reduced, eye gel is added to the eye surface; a semiconductor laser is used to uniformly hit a plurality of laser points at an iris margin; and eye drops are added to the eye surface after laser treatment. The method uses a 532nm laser to hit the iris margin, causes local edema of the iris margin, narrows a passage through which aqueous humor flows from the posterior chamber into the anterior chamber, and increases the pressure of the posterior chamber. The method can keep the high intraocular pressure of the established angle-closure glaucoma animal model between 20-30mmHg, the success rate is 70%, the high intraocular pressure can be maintained for more than one week, no wound is caused on the eye of the animal model, there is no inflammatory reaction on the eye surface, the cornea has no edema and new blood vessels, and the operation of the model can be completed within 10 minutes.

The invention relates to the technical field of biological medicine, in particular to sophocarpine and application of sophocarpine in inhibiting formation of subretinal fibrosis, and the sophocarpine comprises the following steps: selecting 7-week-old male C57BL / 6J mice, adaptively feeding the mice for 1 week, and performing 12-hour illumination / 12-hour dark circulation at the environment temperature of 22-25 DEG C; the method comprises the following steps of: performing intraperitoneal injection of thiobarbital sodium on a C57 mouse fed for 1 week for anesthesia, realizing muscle relaxation by using hypnotic, and anesthetizing ocular surface by using 0.4% tetracaine and 0.5% tropicamide mydriasis; a mouse is randomly divided into a control eye and an experiment eye, and 1 microliter of PBS containing 1.5% of DMSO is injected into the control eye to serve as a carrier for control. The invention finds that injection of sophocarpine in vitreous cavity can inhibit RPE cell epithelial-mesenchymal transition, can be used for preventing or treating age-related macular degeneration subretinal fibrosis, may become a new medicine for treating subretinal fibrosis, has important value for inhibiting EMT of RPE cells, can also inhibit EMT of other cells, and can be used for preventing or treating age-related macular degeneration subretinal fibrosis and treating age-related macular degeneration subretinal fibrosis. Therefore, the method has potential application value on diseases caused by cell EMT.

The invention provides methods, compositions, and kits containing an alphaadrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention discloses a device for distinguishing gaze properties, which comprises a shell, a fixing structure is arranged at the top end of the shell, a black spot generating device is arranged in the shell, a combined mirror is arranged on the black spot generating device, a semi-permeable mirror is arranged at the upper end of the black spot generating device and is inclined, and meanwhile, a silica gel eyeshade and a convex lens are arranged at the left end of the shell. The fixing structure is used for fixing the circle center marking plate, meanwhile, the circle center marking plate is provided with a center alignment device and an alignment device light source, a light source radiator is arranged in the shell, a control key and a card reader are arranged outside the shell, and the combined mirror is a light filtering and dodging combined mirror. The method has the advantages of being low in cost, low in false positive rate, free of mydriasis and the like.

The invention belongs to the field of ophthalmology detection, and particularly relates to a method for rapidly calculating equivalent spherical power and a spherical power value based on eyeball morphological parameters. According to the method, the morphologies of the eyeballs of a person to be measured, including the anterior chamber depth AD, the ocular axis length AL, the crystal thickness LT, the cornea anterior surface K1 value, the cornea anterior surface K2 value and the like, are measured twice, and an adaptive model is provided according to the variation of the morphological parameters of the eyeballs measured twice; and the measured parameter values are substituted into the model according to the model, so that the equivalent spherical power and the numerical value of the spherical power can be quickly and accurately obtained. According to the method provided by the invention, only one time of mydriasis optometry needs to be carried out on children and teenagers within four years, tedious operation of mydriasis in the subsequent examination process is omitted, multiple check coefficients are added into the provided model, and the accuracy of model calculation is relatively high.